AIRS · Airsculpt Technologies, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $151.82M | $180.35M | $195.92M | $168.79M | $62.77M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | - | - | - | - | - |
| SG&A | $82.18M | $98.88M | $102.38M | $101.42M | $23.62M |
| Total Operating Expenses | $163.38M | $182.17M | $186.43M | $173.34M | $52.73M |
| D&A | $12.78M | $11.89M | $10.25M | $8.06M | $5.64M |
| Operating Income | ($11.56M) | ($1.82M) | $9.48M | ($4.54M) | $10.03M |
| Interest Expense | $6.08M | $6.25M | $6.49M | $6.75M | $2.46M |
| Income Tax | ($5.97M) | $188.0K | $7.48M | $3.38M | $0 |
| Net Income | ($11.67M) | ($8.25M) | ($4.48M) | ($14.68M) | $7.58M |
| EPS - Basic | ($0.19) | ($0.14) | ($0.08) | ($0.26) | ($0.01) |
| EPS - Diluted | ($0.19) | ($0.14) | ($0.08) | ($0.26) | ($0.01) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $8.45M | $8.23M | $10.26M | $9.62M | $10.38M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | $5.37M | $6.26M | $3.92M | $3.84M | $2.67M |
| Current Assets | $15.46M | $17.12M | $15.96M | $16.68M | $11.56M |
| Total Assets | $187.30M | $210.00M | $204.02M | $200.76M | $179.61M |
| Current Liabilities | $27.90M | $28.61M | $20.32M | $22.32M | $16.41M |
| Long-term Debt | $50.59M | $65.46M | $69.50M | $81.42M | $81.75M |
| Total Liabilities | $99.59M | $130.71M | $120.03M | $129.99M | $55.93M |
| Stockholders' Equity | $87.71M | $79.29M | $83.99M | $70.77M | $83.53M |
| Retained Earnings | ($40.57M) | ($27.80M) | ($19.55M) | ($15.07M) | ($393.0K) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $3.10M | $11.35M | $23.96M | $24.45M | $13.96M |
| Investing Cash Flow | ($2.40M) | ($14.01M) | ($9.92M) | ($12.92M) | ($3.69M) |
| Financing Cash Flow | ($478.0K) | $630.0K | ($13.39M) | ($27.26M) | ($5.02M) |
| CapEx | $2.40M | $14.01M | $9.92M | $12.92M | $3.69M |
| Free Cash Flow | $692.0K | ($2.66M) | $14.04M | $11.53M | $10.27M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | -7.6% | -1.0% | 4.8% | -2.7% | 16.0% |
| EBITDA margin | 0.8% | 5.6% | 10.1% | 2.1% | 25.0% |
| Net margin | -7.7% | -4.6% | -2.3% | -8.7% | 12.1% |
| Free cash flow margin | 0.5% | -1.5% | 7.2% | 6.8% | 16.4% |
| FCF / Net income | -0.06 | 0.32 | -3.13 | -0.79 | 1.36 |
| R&D / Revenue | - | - | - | - | - |
| SG&A / Revenue | 54.1% | 54.8% | 52.3% | 60.1% | 37.6% |
| Effective tax rate | - | - | 249.4% | - | 0.0% |
| Return on assets | -6.2% | -3.9% | -2.2% | -7.3% | 4.2% |
| Return on equity | -13.3% | -10.4% | -5.3% | -20.7% | 9.1% |
| Return on invested capital | -6.6% | -1.0% | 3.1% | -2.4% | 6.1% |
| Liquidity | |||||
| Current ratio | 0.55 | 0.60 | 0.79 | 0.75 | 0.70 |
| Quick ratio | 0.55 | 0.60 | 0.79 | 0.75 | 0.70 |
| Cash ratio | 0.30 | 0.29 | 0.51 | 0.43 | 0.63 |
| Leverage | |||||
| Debt / Equity | 0.58 | 0.83 | 0.83 | 1.15 | 0.98 |
| Debt / Assets | 0.27 | 0.31 | 0.34 | 0.41 | 0.46 |
| Debt / EBITDA | 41.43 | 6.50 | 3.52 | 23.16 | 5.22 |
| Interest coverage | -1.9x | -0.3x | 1.5x | -0.7x | 4.1x |
| Equity multiplier | 2.14 | 2.65 | 2.43 | 2.84 | 2.15 |
| Liabilities / Assets | 0.53 | 0.62 | 0.59 | 0.65 | 0.31 |
| Efficiency | |||||
| Asset turnover | 0.81 | 0.86 | 0.96 | 0.84 | 0.35 |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | 1.4x | 3.8x | 5.1x | 2.9x | 11.5x |
| P / S | 0.8x | 1.7x | 2.2x | 1.2x | 15.2x |
| EV / EBITDA | 132.5x | 35.4x | 24.5x | 79.0x | 65.6x |
| Growth | |||||
| Revenue growth (YoY) | -15.8% | -7.9% | 16.1% | 168.9% | - |
| Revenue CAGR (3y) | -3.5% | 42.2% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | -536.6% | - | - | - | - |
| Net income growth (YoY) | -41.4% | -84.2% | 69.5% | - | - |
| EPS growth (YoY) | -35.7% | -75.0% | 69.2% | -2500.0% | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | - | - | 21.8% | 12.3% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | 10.6% | -5.6% | 18.7% | -15.3% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$151.82M totalReportable Segment$151.82M · 100.0%
Geographic
$4.60M totalNon Us$4.60M · 100.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
0.76
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Services-Offices & Clinics of Doctors of Medicine
Comparing Airsculpt Technologies against the 5 most active filers in the same SIC group.
Dividends
$0.00/share trailing 12 months
| Ex-date | Per share |
|---|---|
| Aug 25, 2022 | $0.4100 |